Development of pulmonary tuberculosis in the patient with systemic sarcoidosis and brain involvement

The article presents a clinical case of pulmonary tuberculosis with destruction and bacterial excretion in the patient with systemic sarcoidosis and cerebral lesions. Tuberculosis was characterized by the infiltrate and cavity in S1+2 of the left lung, tuberculous mycobacteria were detected by microscopy, GeneXpertMBT/Rif, and culture. Systemic sarcoidosis with brain involvement was diagnosed based on intrathoracic lymphadenopathy in 2015, development of dissemination in the lungs and neurological symptoms by 2018, deterioration of changes by 2019, rapid partial resolution of foci in the lungs, and moderate regression of neurological disorders during the treatment with prednisolone. A full course of anti-tuberculosis chemotherapy (316 doses) resulted in persistent sputum conversion, resolution of the infiltrate and cavity healing. Prednisolone was administered simultaneously for 318 days with increased doses (45-35 mg) for the first 2 months, then titrated down to 15 mg and remained so until the end of the treatment with gradual reduction and discontinuation. Changes in the lungs and improvement of clinical and radiological manifestations of neurosarcoidosis were documented.

Is neoadjuvant chemotherapy necessary for the surgical treatment of renal tuberculosis?

The relevance of urogenital tuberculosis remains high as well as its social significance. With the advent of anti-tuberculosis drugs it became possible to perform organ-preserving surgeries, both anti-tuberculosis chemotherapy in the preoperative period and after surgery is extremely important. Violation of this principle leads to the development of severe complications, which is demonstrated by clinical observation. Patient I., female 40 years. Diagnosis: polycavernous tuberculosis of the right kidney, cavernous tuberculosis of the left kidney, bladder tuberculosis of stage 4 (microcystis). Her anti-tuberculosis therapy was irregular and occasionally. In the general urology department a laparoscopic nephrectomy on the right and nephrostomy on the left were performed. Anti-tuberculosis therapy was discontinued, which led to the progression of renal failure and repeated attacks of pyelonephritis. In this regards she was re-operated in the Avicenna Medical Center: laparoscopic cavernotomy of the left solitary kidney and cystectomy with enterocystoplasty by Studer were performed. In the postoperative period a reservoir-uterine fistula was formed. She did not receive anti-tuberculosis therapy. The patient returned to the Avicenna Medical Center after 9 months, laparoscopic removal of the shrunken intestinal reservoir was performed with the formation of Bricker ileal conduit with a good short-term and long-term (follow-up period of 10 months) result.

Toxicological Effects of Antituberculosic Chemotherapy in Adults: An Integrative Literature Review

Objective: To analyze the toxicological effects of anti-tuberculosis chemotherapy in adults in national and international literature in the period from 2015 to 2020. Methodology: It is a qualitative descriptive research, of the type Integrative Literature Review (ILR). In the VHL databases PubMed / Medline, Arca, Web of Science, Microsoft Academic and Cochrane Library. Data analysis was performed with the aid of the IRaMuTeQ software. Results: 36 articles were found in which the following categories were created: 1) Association of hepatotoxicity and appearance of liver damage; 2) The incidence of adverse events related to antituberculin therapy; 3) Risk factors of regular consumption of antituberculins; 4) Intensive renal treatment for patients with nephrotoxicity. Conclusion: in our review we identified that the elderly, HIV positive and alcohol users are more likely to have toxicological effects during treatment, which can lead to a possible abandonment of treatment.

Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin

Tuberculosis remains one of the most dangerous and widespread infectious diseases. More than 20 medicinal products are currently available for the treatment of tuberculosis. One of the most serious adverse drug reactions (ADRs) associated with anti-tuberculosis medicines is hepatotoxicity.The aim of the study was to assess the effect of polymorphic markers of the NAT2 gene on the ADR risk in patients with pulmonary tuberculosis who received isoniazid and rifampicin.Materials and methods. The study included 67 patients with different forms of pulmonary tuberculosis who received combination therapy with isoniazid and rifampicin. Single nucleotide polymorphisms (SNPs) of the NAT2 gene were determined by real-time PCR. Statistical processing was performed using SPSS Statistics 20.0.Results: Six SNPs were identified in the NAT2 gene. Based on these SNPs the following phenotypes were determined by the rate of NAT2 acetylation: fast acetylators—6 subjects, intermediate acetylators—24 subjects, and slow acetylators—37 subjects. The study assessed the relationship between the acetylator phenotype and the development of ADRs during combination therapy with isoniazid and rifampicin. Slow acetylators had a significantly greater increase in total bilirubin level (p=0.011) compared to intermediate acetylators. Loss of appetite was more often observed in fast acetylators than in intermediate acetylators (p=0.021).Conclusions. The obtained data suggest interrelation between the slow type of NAT2 acetylation and the risk of ADRs in patients undergoing pulmonary tuberculosis chemotherapy with isoniazid and rifampicin. Out of all the ADRs registered in the study, the fast acetylators were more likely to have loss of appetite, however, the expansion of the study population is needed to verify this observation. The studied polymorphisms have an impact on the development of ADRs in patients undergoing pulmonary tuberculosis chemotherapy with isoniazid and rifampicin and may be used to predict the safety profile of pharmacotherapy in this group of patients.

Postponed treatment outcomes in patients with limited fibrous cavernous pulmonary tuberculosis with use of valve bronchial block

The objective of the study: to evaluate postponed outcomes of comprehensive treatment with use of valve bronchial block in patients with limited fibrous cavernous pulmonary tuberculosis.Subjects and methods. Treatment outcomes of 97 patients suffering from chronic destructive pulmonary tuberculosis with lesions within one lobe were analyzed. Valve bronchial block (VBB+) was used in 42 patients, and it was not used in 55 patients (VBB-). In addition to anti-tuberculosis chemotherapy, artificial pneumoperitoneum was used in all patients as a part of the treatment.Results. Postpones treatment outcomes were followed in 83 patients: in 38 from the Group VBB+ and in 45 from Group VBB-. Clinical cure was achieved in 28/38 (66.7%) patients in Group VBB+ and in 16/45 (29.1%) in Group VBB-, p <0.01. A lethal outcome was registered in 2 (4.8%) patients in Group VBB+ and 10 (18.1%) in Group VBB-, p <0.03.

Justifcation for the usage of mineral water of Teberda deposit in the treatment of patients with focal pulmonary tuberculosis

The purpose of the research is scientifically substantiate the use of drinking mineral waters (MW) of Teberdinskiy deposit in sanatorium and spa treatment of patients suffering from focal pulmonary tuberculosis (FPT). Material and methods. The study included 80 patients with FPT in the resorption and carnification phase. By random sampling, we formed 2 groups: the control group (CG; 40 people) that received inhalations with 1% dioxidin solution and a standard drug anti-tuberculosis chemotherapy; the patients of the group of comparison (GC; 40 people) additionally received drinking MW "Teberda." Results. The analysis of clinical symptom dynamics did not show any significant differences between the groups: by the end of sanatorium-and-spa treatment the leveling of clinical symptoms in the MG was with 98.3% of the cases, in the CG with 88.8%. The patients of the MG had a normalization of related T-lymphocyte subpopulations, immunoregulatory index decreased by 39.2% (p 0.01), there was a drop in intensity of free radical oxidation by 30.2% (p 0.01), an increase in activity of antioxidant protection system by 17.2% (p 0.05). The CG had only a tendency to improvement of laboratory indicators. Conclusion. In order to achieve a higher therapeutic effect having FPT in the resorption and carnification phase, it is advisable to include drinking MW in the treatment program, which expands and complements the possibilities of rehabilitation and rehabilitation assistance to the given group of patients.

A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy

Alternative ways to prevent and treat infectious diseases are needed. Previously, we identified a fungal peptide, NZX, that was comparable to rifampicin in lowering M. tuberculosis load in a murine tuberculosis (TB) infection model. Here we assessed the potential synergy between this cationic host defence peptide (CHDP) and the current TB drugs and analysed its pharmacokinetics. We found additive effect of this peptide with isoniazid and ethambutol and confirmed these results with ethambutol in a murine TB-model. In vivo, the peptide remained stable in circulation and preserved lung structure better than ethambutol alone. Antibiotic resistance studies did not induce mutants with reduced susceptibility to the peptide. We further observed that this peptide was effective against nontuberculous mycobacteria (NTM), such as M. avium and M. abscessus, and several Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. In conclusion, the presented data supports a role for this CHDP in the treatment of drug resistant organisms.

Comparative aetio-epidemiological analysis of lung tuberculosis versus sarcoidosis: classical and new concepts

The review presents data on two similar granulomatous inflammatory diseases: tuberculosis and sarcoidosis of the lungs, which together cover about 5% of all pulmonary pathology, albeit occur with different incidence (20 : 1). Despite the established aetiology of tuberculosis, the disease has not disappeared and nowadays has even acquired a new urgency: It is getting out of control due to growing poverty, the comorbidity with HIV infection, increasing cases of drug resistance of Mycobacteria, insufficient effectiveness and the growing costs of its treatment. Against the background of the expansion of anthropogenic influences and other environmental impacts on the immune system, the incidence of lung sarcoidosis is also increasing, while patients are initially often misdiagnosed with tuberculosis, with resulting unjustified anti-tuberculosis chemotherapy, leading to chronization of the disease with frequent relapses and, accordingly, to an increase in disability and mortality rates. In recent years, clinical manifestations of sarcoidosis due to a variety of trigger aetiological factors with adjuvant-like action (from Mycobacteria to xenobiotics) are considered by a number of authors as a variant of autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA). The article emphasizes the similarity of two granulomatous inflammatory diseases and the concept of two variants of the bodys response to similar or even identical aetiological factors within different human reactivity (possibly on a different mosaic/permissive background). In brief the newest data on experimental models of sarcoidosis are reviewed as well as the role of autophagy disorders and opposite macrophageal polarization in tuberculosis versus sarcoidosis. Authors coined the original hypothesis of the possible therapeutic effectiveness of Rapamycin in sarcoidosis and for the first time posed a question of equivocal character of comorbidity between these granulomatoses and COVID-19 infection.